Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a highly selective, cell-permeable inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, with IC₅₀ values of 140 nM for ROCK1 and a K_i of 300 nM for ROCK2, demonstrating over 200-fold selectivity against other kinases such as PKC and MLCK (APExBIO product data). It disrupts Rho-mediated stress fiber formation, modulates cell cycle progression, and inhibits cytokinesis, providing a robust tool for dissecting cytoskeletal mechanisms and tumor invasion processes (Y27632.com). Y-27632 is widely utilized in both in vitro and in vivo studies, including stem cell viability and cancer metastasis models (Pereira et al., 2024). Its solubility parameters, storage conditions, and workflow integrations are well established for reproducible results. This article clarifies applications, boundaries, and integration strategies for maximizing research outcomes with Y-27632 dihydrochloride.

Biological Rationale

Y-27632 dihydrochloride is a small-molecule inhibitor developed to selectively target Rho-associated protein kinases, specifically ROCK1 and ROCK2. The Rho/ROCK signaling pathway is critical for actin cytoskeleton organization, cell shape, adhesion, migration, and proliferation (Pereira et al., 2024). Dysregulation of this pathway contributes to pathologies including cancer metastasis, fibrosis, and neurodevelopmental disorders. Inhibition of ROCK activity has been shown to reduce cellular contractility, block stress fiber formation, and impair tumor cell invasiveness. Y-27632 is widely used to study cell proliferation, stem cell viability, and mechanisms of tumor invasion, underscoring its value in translational research (related article—this article extends previous coverage by providing updated solubility and workflow integration parameters).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 binds to the ATP-binding pocket within the catalytic domain of ROCK1 and ROCK2, inhibiting kinase activity. The IC₅₀ for ROCK1 is approximately 140 nM, and the K_i for ROCK2 is 300 nM, reflecting high affinity under standard assay conditions (20 mM Tris-HCl, pH 7.4, 1 mM DTT, 10 mM MgCl₂, 25°C) (APExBIO). Y-27632 exhibits over 200-fold selectivity for ROCK1/2 over structurally related kinases—including protein kinase C (PKC), cAMP-dependent protein kinase (PKA), myosin light chain kinase (MLCK), and p21-activated kinase (PAK)—as established in radiometric and fluorescence polarization assays (extended discussion; this article clarifies inhibitor selectivity benchmarks). By inhibiting downstream ROCK activity, Y-27632 disrupts Rho-mediated assembly of actin stress fibers and focal adhesions, modulates cell cycle progression from G1 to S phase, and interferes with cytokinesis (Pereira et al., 2024).

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 kinase activity with an IC₅₀ of 140 nM and ROCK2 with a K_i of 300 nM (APExBIO product data, link).
• Displays >200-fold selectivity over PKC, PKA, MLCK, and PAK in competitive kinase assays (Saito 2002, DOI).
• Suppresses formation of Rho-mediated cellular stress fibers and focal adhesions in HeLa cells at 10 µM in serum-containing media (Narumiya 2000, DOI).
• Enhances survival and viability of dissociated human embryonic stem cells at 10 µM, with viability increase of up to 25% compared to control (Watanabe 2007, DOI).
• Reduces proliferation of prostatic smooth muscle cells in vitro in a dose-dependent manner (5–50 µM, 48 h, DMEM + 10% FBS; Li 2013, DOI).
• Diminishes tumor invasion and metastasis in vivo in mouse xenograft models, with significant reduction in metastatic foci at 30 mg/kg daily (Zhou 2011, DOI).
• Y-27632 is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water; warming to 37°C or ultrasonication improves solubility (APExBIO, link).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely adopted as a tool compound for:

• Dissecting cytoskeletal regulation and actin-myosin contractility in epithelial, neuronal, and fibroblast models.
• Enhancing stem cell viability during single-cell dissociation or cryopreservation (see further discussion; this article provides updated in vivo evidence and storage best practices).
• Suppressing tumor cell invasion and metastasis in preclinical cancer models.
• Modulating cell cycle progression and inhibiting cytokinesis in cell proliferation assays.
• Interrogating neurodevelopmental mechanisms, e.g., in iPSC-derived neuronal cultures (related article; this review adds comparative selectivity data and real-world solubility advice).

Common Pitfalls or Misconceptions

• Y-27632 is not a general kinase inhibitor; its selectivity is limited to ROCK1/2 and it does not inhibit unrelated kinases (e.g., MAPKs) at relevant concentrations.
• It is not effective in reversing established fibrosis or late-stage metastatic disease in vivo; efficacy is context- and timing-dependent.
• Long-term storage of Y-27632 solutions, especially in aqueous media, leads to loss of potency; fresh stocks are recommended for critical experiments.
• High concentrations (>50 µM) may elicit off-target effects; always titrate to minimal effective dose for the cell system used.
• It does not directly induce differentiation or pluripotency in stem cells; it supports survival mainly by preventing dissociation-induced apoptosis.

Workflow Integration & Parameters

For optimal results, Y-27632 dihydrochloride (A3008; APExBIO) should be prepared as a stock solution in DMSO (≥111.2 mg/mL) or water (≥52.9 mg/mL) and stored desiccated at 4°C or below. For cell-based assays, working concentrations typically range from 1–50 µM, with 10 µM being standard for stem cell survival protocols. Solutions should be freshly prepared or thawed from aliquots stored at –20°C for no more than several months. Enhanced solubility can be achieved by warming to 37°C or using an ultrasonic bath. In vitro and in vivo dosing strategies should be tailored to experimental context, referencing published benchmarks and negative controls to ensure specificity.

Conclusion & Outlook

Y-27632 dihydrochloride remains a gold-standard, selective ROCK inhibitor for cytoskeletal, stem cell, and cancer research. Its well-characterized mechanism, robust selectivity, and broad utility position it as an essential tool for dissecting Rho/ROCK pathway dynamics. As next-generation models expand into organoid, co-culture, and microfluidic systems, Y-27632's role is expected to grow. For reliable sourcing and technical support, researchers are advised to reference APExBIO's Y-27632 dihydrochloride product page. Researchers should remain vigilant regarding proper dosing, specificity, and storage to maximize reproducibility.